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Abstract: Plants with high amounts of antioxidants may be a promising therapy for preventing
and curing UV-induced oxidative skin damage. The objective of this study was to verify the
efficacy of topical formulations containing dissolved and suspended Silybum marianum extract
against UVB-induced oxidative stress in guinea pig and HaCaT keratinocytes. Herbal extract was
dissolved in Transcutol HP (TC) and sucrose-esters were incorporated as penetration enhancers
in creams. Biocompatibility of compositions was tested on HeLa cells and HaCaT keratinocytes
as in vitro models. Transepidermal water loss (TEWL) tests were performed to prove the safety
of formulations in vivo. Drug release of different compositions was assessed by Franz diffusion
methods. Superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and lipid
peroxidation (MDA) activities were evaluated before and after UVB irradiation in a guinea pig model
and HaCaT cells. Heme oxygenase-1 (HO-1) enzyme activity was measured in the epidermis of
guinea pigs treated by different creams before and after UVB irradiation. Treatment with compositions
containing silymarin powder (SM) dissolved in TC and sucrose stearate SP 50 or SP 70 resulted in
increased activities of all reactive oxygen species (ROS) eliminating enzymes in the case of pre- and
post-treatment as well. Reduction in the levels of lipid peroxidation end products was also detected
after treatment with these two compositions. Post-treatment was more effective as the increase of
the activity of antioxidants was higher. Lower HO-1 enzyme levels were measured in the case of
pre- and post-treatment groups compared to control groups. Therefore, this study demonstrates
the effectiveness of topical formulations containing silymarin in inhibiting UVB irradiation induced
oxidative stress of the skin.
Keywords: silymarin; antioxidants; transcutol; sucrose esters; topical formulations; UVB-induced
oxidative stress; HO-1 enzyme
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1. Introduction
Silybum marianum (Milk thistle) is a well-known medicinal plant that has been used for centuries
as a herbal medicine for the treatment of liver-related diseases [1]. Many reviews have been
published focusing on the determination and separation of active compounds in this herb [2].
Flavonolignan and non-flavonolignan components were separated from the Silybum marianum complex
by a high performance liquid chromatography/tandem mass spectrometry (HPLC-MS/MS) method [3].
The major bioactive flavonolignans include silychristins A and B, silydianin, silybin A and B,
isosilybin A and B. Furthermore, three additional components were also detected and partly separated,
presumably two silybin stereoisomers and one isosilybin stereoisomer [4]. These components
possess a wide range of antioxidant, cell regenerating and anticancer effects in the case of peroral
application. [5]. Several articles have dealt with the topical application of Silybum marianum extract,
mainly on the protective effects of silymarin and silybin against UVB-induced skin damage [6].
Overexposure of the skin to UV radiation causes sunburn, inflammation, oxidative stress, DNA
damage, suppression of the immune system and skin cancers [7]. Both UVB (290–320 nm) and UVA
(320–400 nm) induce the generation of ROS, which create oxidative stress in skin cells and play
an essential role in the initiation, promotion and progression of skin aging and carcinogenesis [8].
Silybinin significantly decreased ROS production and apoptosis in HaCaT cells in a dose-dependent
level after UVA irradiation [9]. To regulate ROS levels, the skin is rich in enzymatic (SOD, CAT, GPX)
and non-enzymatic (reduced glutathione, ascorbic acid, ubiquinol and tocopherol) [10,11] antioxidant
defense systems, thereby maintains physiological “own-redox” homeostasis.
UV-generated ROS affect the regulation of the gene expression of signaling molecules/cascades
such as mitogen-activated protein-kinases and interrelated inflammatory cytokines as well [12].
Supporting the skin’s own protective mechanism by exogenous application of natural compounds
(i.e., silymarin) is one approach for topical photoprotection [13]. Nucleotide excision repair mechanism
is also responsible for the protective effect of silymarin on epidermal keratinocytes from ultraviolet
radiation-induced apoptosis and DNA damage [14].
In additional to the classic antioxidant defense, the cytoprotective enzyme heme oxygenase
exhibits antioxidant properties. HO-1 cleaves heme into three products: biliverdin, CO, and ferrous
iron. Biliverdin is further reduced to an antioxidant effector molecule bilirubin [15,16]. Induction
of HO-1 also a potent anti-inflammatory intracellular mediator and can cause anti-apoptotic effect
as well [16].
Topical silymarin was demonstrated to have remarkable antitumor effects [17]. The molecular
mechanism of inhibition of photocacinogenesis by cutaneous silymarin is based on its anti-oxidant and
anti-inflammatory effects. Additionally, many studies have also reported on the effect of silymarin on
UVB-induced suppression of immune responses and DNA damaging effects in the skin [18]. Cutaneous
silymarin formulations may favorably supplement protection of sunscreens and may be useful in the
treatment of skin diseases associated with UV radiation-induced inflammation and oxidative stress
and skin cancer [19,20].
However, the low solubility and low bioavailability of silymarin limits extensive topical
applicability [21]. Many methods and dosage forms have been described for optimizing these
parameters [22,23]. As penetration enhancers surfactants are able to influence the barrier integrity of
the skin and potentiate the transport mechanisms of active pharmaceutical ingredients (APIs) [24].
However, only a few articles have dealt with the potential of well-designed carrier systems, but the
liberation and absorption of APIs may be affected by the use of ideal topical carriers [25]. Due to the
relative impermeability of the stratum corneum, extensive preformulation studies are necessary in
order to develop topical vehicles with optimal drug release and skin penetration [26].
Therefore, the aim of the present study was to design new hydrophilic topical formulations
containing SM. In the first stage of our experiment, different creams are prepared. The novelty
of our formulations is the concomitant application of different surfactants (three sucrose esters,
polysorbate 60 and Cremophor) and a solvent (Transcutol). These components may increase
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the bioavailability, solubility and penetration of SM. Texture analysis and in vitro release studies
were performed to qualify the biopharmaceutical properties of our ten compositions. Appropriate
viscosity/consistency of compositions was measured by texture analysis investigation. We conducted
in vitro dissolution studies to compare SM dissolution from our cream compositions. Diffusion
coefficients and release rates were also determined. These parameters refer to the kinetic profile of
SM permeation through the skin. Many studies have reported on the toxicity and the irritancy of
these applied surfactants and cream bases [27]. Biocompatibility tests were performed to certify the
harmlessness of these compositions. The carrier systems containing SM were tested on HeLa cells
and on HaCaT keratinocytes. In vivo irritancy tests (TEWL) were also performed to characterize
epidermal barrier function 24 h after application of creams. Transepidermal water loss measurement
is one of the standard methods used to analyse the integrity of skin barrier treated with topically
applied substances.
Four compositions were selected on the basis of these biopharmaceutical and biocompatibility
tests. In the second stage of our experiment, we measured the in vitro antioxidant activities of selected
formulations (Compositions III and IV and VIII and IX) on HaCaT cells and in vivo guinea pig
animal model to demonstrate the efficacy of our topical formulations against UVB irradiation-caused
significant oxidative stress via generation of reactive oxygen species (ROS) and these ROS’ rapid
removal by non-enzymatic and enzymatic antioxidants. Therefore, different enzyme activities
(glutathione peroxidase, GPX; superoxide dismutase, SOD; catalase, CAT) were determined. Lipid
peroxidase tests were also performed and the level of malondialdehyde (MDA) was determined.
Finally, heme-oxygenase (HO-1) enzyme activity was also measured in skin tissue of guinea pigs
before and after UVB irradiation, because induction of HO-1 may protect against the cytotoxicity
caused by oxidative stress.
2. Results
2.1. Texture Analyzer Studies
Resistance of the different silymarin creams compositions (Table 1) showed different values during
the compression tests.
Table 1. The composition of the silymarin creams.
Composition
Emulgents Cetostearyl Alcohol (4.6 g) Stearic Acid
(10 g) Propylene Glycol (5 g) IPM (5 g)
Nipagin M (1 g) Purified water (ad 100 g)
SM
(5 g)
TC
(14.2 g)
P60
(3 g)
CRC
(3 g)
SP 50
(3 g)
SP 70
(3 g)
PS 750
(3 g)
I + + +
II + + +
III + + +
IV + + +
V + + +
VI + + + +
VII + + + +
VIII + + + +
IX + + + +
X + + + +
Abbreviations: SM (silymarin powder), TC (Transcutol HP), P60 (Polysorbate 60), CRC (Cremophor A6 and A25
in the ratio 1:1), SP 50 (sucrose stearate SP 50), SP 70 (sucrose stearate SP 70), PS 750 (sucrose stearate PS 750),
IPM (isopropyl myristate).
The force (N) needed for the probe to penetrate into the creams is shown in Figure 1. Differences
in compression force among the formulations I–X were measured. However, the resistance of creams
containing SM in dissolved form with TC showed lower values compared to those formulations with
the same emulgent where SM was in suspended form. Significant (p < 0.05) differences were detected
between compositions I and V, III and VIII, IV and IX, V and X. Lower resistance values are more
desirable for the sake of applicability. Higher compression force values were measured in the case
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of hard cream consistency. These hard composition structures may hinder the liberation of active
pharmaceutical ingredients. Each data point represents the mean ± S.D., n = 5. Repeated-Measures
ANOVA and for quantifying associations between the groups, Pearson correlation has been performed.
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Figure 1. Resistance of silymarin cream formulations I–X, determined as compression force (N). Each 
data point represents the mean ± S.D., n = 5. Repeated-Measures ANOVA and for quantifying 
associations between the groups, Pearson correlation had been performed. Significant differences 
were marked in the figure with * (p < 0.01), and ** (p < 0.1), which show the significance levels in the 
case of compositions containing SM in suspended or dissolved forms. 
2.2. In Vitro Release Studies of Silymarin 
Figure 2 shows the cumulative amount per unit area of silymarin diffused from the different 
formulations I–X against square root of time across isopropyl myristate (IPM) impregnated cellulose–
acetate membrane. Each data point represents the mean ± S.D. of five experiments. Compositions in 
which SM was previously dissolved in TC resulted in the best diffusion values. 
It was observed that the release of drug from the different formulae can be ranked in the 
following descending order: IX  ˃VIII  ˃X  ˃VII  ˃VI  ˃III  ˃IV  ˃V  ˃II  ˃I. Those creams that contained 
SM in dissolved form with the same emulgent showed higher diffusion values compared to suspended 
SM compositions. Significant differences (p < 0.05) could be detected between the dissolution of 
compositions II and VII, III and VIII, IV and IX, V and X. Our results showed that the drug release 
was better from compositions containing sucrose stearate SP50 or SP70 as emulsifying agent. The best 
diffusion was achieved from formulation IX, in which SM was dissolved in TC and the emulsifying 
agent was SP70, for which the diffused amount of API was 7083.47 ± 40.41 μg/cm2. Repeated-
Measures ANOVA and for quantifying associations between the groups, Pearson correlation was 
been performed. Significant differences are marked in the figures with asterisks, which show the 
significance levels in the case of compositions containing SM in suspended or dissolved forms. 
Silymarin release rate, k was determined from the slope of the amount of drug released per unit 
area versus the square root of time. The apparent diffusion coefficient (D) of the drug within the 
vehicle was estimated from the release rate value. Release rates and diffusion coefficient values are 
listed in Table 2 [28,29]. Significant differences (p < 0.05) could be seen between the diffusion 
coefficient values of compositions II and VII, III and VIII, IV and IX, V and X. Repeated-Measures 
ANOVA and Pearson correlation tests were performed. Significant differences are marked with 
asterisks in the figure, showing the significance levels in the case of compositions containing SM in 
suspended or dissolved forms. 
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2.2. In Vitro Release Studies of Silymarin
Figure 2 sho s the cu ulative a ount per unit area of sily arin diffused fro the different
for ulations I–X against square root of time across isopropyl myristate (IPM) impregnated
cellulose–acetate membrane. Each data point represents the mean ± S.D. of five experiments.
Compositions in which SM was previously dissolved in TC resulted in the best diffusion values.
It as observed that the release of drug fro the different for ulae can be ranked in the
follo ing descending order: IX > VIII > X > VII > VI > III > IV > V > II > I. Those creams that
contained SM in dissolved form with the same emulgent showed higher diffusion values compared
to suspended SM compositions. Significant differences (p < 0.05) could be detected between the
dissolution of compositions II and VII, III and VIII, IV and IX, V and X. Our results showed that the
drug release was better from compositions containing sucrose stearate SP50 or SP70 as emulsifying
agent. The best diffusion was achieved from formulation IX, in which SM was dissolved in TC and
the emulsifying agent was SP70, for which the diffused amount of API was 7083.47 ± 40.41 µg/cm2.
Repeated-Measures ANOVA and for quantifying associations between the groups, Pearson correlation
was been performed. Significant differences are marked in the figures with asterisks, which show the
significance levels in the case of co positions containing S in suspended or dissolved for s.
Sily arin release rate, k was deter ined fro the slope of the a ount of drug released per unit
area versus the square root of ti e. The apparent diffusion coefficient (D) of the drug within the
vehicle was esti ated fro the release rate value. Release rates and diffusion coefficient values are
listed in Table 2 [28,29]. Significant differences (p < 0.05) could be seen between the diffusion coefficient
values of compositions II and VII, III and VIII, IV and IX, V and X. Repeated-Measures ANOVA and
Pearson correlation tests were performed. Significant differences are marked with asterisks in the
figure, showing the significance levels in the case of compositions containing SM in suspended or
dissolved forms.
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Figure 2. Release profiles of SM across isopropyl myristate (IPM) impregnated cellulose-acetate membrane 
of the formulations I–X. Each point represents the mean ± S.D. of five experiments. Repeated-Measures 
Anova and Pearson correlation tests were performed. Significant differences (p > 0.05) were marked 
with * in the figure. The asterisks show the significance levels in the case of compositions containing 
SM in suspended or dissolved forms. 
Table 2. Silymarin release rate and the diffusion coefficient values of the compositions (I–X). Each 
data point represents the mean ± S.D., n = 5, p > 0.05. Repeated-Measures Anova and Pearson 
correlation tests were performed. Significant differences are marked with * in the table. * show the 
significance levels in the case of compositions containing SM in suspended or dissolved forms. 
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I 0.075 ± 0.12 0.21 ± 0.02 
II 1.30 ± 0.32 0.73 ± 0.05 
III 1.41 ± 0.33 1.36 ± 0.23 
IV 2.01 ± 0.23 1.57 ± 0.25 
V 4.24 ± 0.14 0.71 ± 0.23 
VI 2.00 ± 0.31 0.93 ± 0.25 
VII 5.94 ± 0.45 24.1 ± 0.24 * 
VIII 4.68 ± 0.26 47.23 ± 0.42 * 
IX 4.71 ± 0.13 30.22 ± 0.20 * 
X 3.99 ± 0.35 18.00 ± 0.13 * 
2.3. MTT Cytotoxicity Tests 
Compositions I–X were tested with MTT cytotoxicity tests on both HeLa and HaCaT cell lines. 
Each composition was more toxic to HaCaT cells. Cell viability values ranked in the following 
descending order among the compositions containing emulgents SP 70 > SP 50 > P60 > PS 750 = CRC, 
for both the HeLa and HaCaT cell line. SP 70 was less toxic among the emulgents, the cell viability 
was 48.05% ± 0.6% on HeLa and 53.7% ± 0.6% on HaCaT cells. Those compositions which contain 
sucrose esters (SP 50 and 70, compositions III and IV, VIII and IX) as emulsifying agent resulted in 
satisfactory viability values. The cell viability values were compared to the positive control Triton × 
Figure 2. Release profiles of SM across isopropyl myristate (IPM) impregnated cellulose-acetate
membrane of the formulations I–X. Each point represents the mean ± S.D. of five experiments.
Repeated-Measures Anova and Pearson correlation tests were performed. Significant differences
(p > 0.05) were marked with * in the figure. The asterisks show the significance levels in the case of
compositions containing SM in suspended or dissolved forms.
Table 2. Silymarin release rate and the diffusion coefficient values of the compositions (I–X). Each data
point represents the mean ± S.D., n = 5, p > 0.05. Repeated-Measures Anova and Pearson correlation
tests were performed. Significant differences are marked with * in the table. * show the significance
levels in the case of compositions containing SM in suspended or dissolved forms.
Composition
Release Rate Diffusion Coefficient
k·102 (µg/cm2·min1/2) ± S.D. D 105 (cm2/min) ± S.D.
I 0.075 1 0.21 ± 0.02
II 1.30 ± .32 0.73 ± 0.05
III 1.41 ± 0.33 1.36 ± 0.23
IV 2.01 ± 0.23 1.57 ± 0.25
V 4.24 ± 0.14 0.71 ± 0.23
VI 2.00 ± 0.31 0.93 ± 0.25
VII 5.94 ± 0.45 24.1 ± 0.24 *
VIII 4.68 ± 0.26 47.23 ± 0.42 *
IX 4.71 ± 0.13 30.22 ± 0.20 *
X 3.99 ± 0.35 18.00 ± 0.13 *
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sucrose esters (SP 50 and 70, compositions III and IV, VIII and IX) as emulsifying agent resulted
in satisfactory viability values. The cell viability values were compared to the positive control
Triton × 100. A significant (p < 0.05) increase was detected in compositions I, III, IV, VIII and IX
on HeLa cells and III, IV, VIII on HaCaT keratinocytes. Each data point represents the mean ± S.D.,
n = 10. Repeated-Measures ANOVA and Pearson correlation tests were performed (Figure 3).
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However no significant increase was observed before and after 24 h application for either of the 
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The effect of SM cream formulations III, IV, VIII, and IX against UVB irradiation was examined 
on the HaCaT cell line. Figure 5 shows the results of in vitro antioxidant activity measurements. The 
GPx (Figure 5a), SOD (Figure 5b) and CAT (Figure 5c) activities were decreased in control groups 
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the post-treatment with the compositions inc e sed the antioxidant activity of the enzymes.
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performed. Significant differences were marked with *, which show the significance levels in the case 
of compositions VIII and IX before and after 24 h compared to the untreated controls. 
Differences among the compositions could be observed as well: cream bases containing SM in 
dissolved or in suspended form prevented better the UV-B induced decrease in antioxidant activity 
of skin tissues in these three antioxidant tests compared to those controls which do not contain active 
substances (pre/post controls SP 50, SP 70). GPX level increased significantly (p < 0.05) in both pre- 
and post-treatment of the compositions compared to control groups. Significant (p < 0.05) increases 
were also detected after the pretreatment with compositions III, IV, VIII and IX in the level of SOD, 
but no significant (p < 0.05) increase was shown in CAT levels compared to control groups. The level 
of MDA (Figure 5d) in control groups and in the UVB-treated group increased after UVB exposure 
compared to the untreated group. It was observed that pre-treatment and post-treatment with 
compositions III, IV, and VIII, IX decreased the level of MDA, however compositions VIII, and IX, 
caused more reduction in the end product of lipid peroxidation. In the pretreatment and 
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Figure 4. In vivo skin irritation exa ination. Changes in TE L value before and after 24 h application
of the selected sily arin crea s III, I , III, IX on the dorsal skin of guinea pigs. Each data point
represents the ean S. ., n = 5. epeated- easures and Pearson correlation tests ere
erfor e . Significant ifferences ere arke ith *, hich sho the significance levels in the case
f c siti s III a I ef re a after 24 c ared to the untreated controls.
Differences among the compositions could be observed as well: cream bases containing SM in
dissolved or in suspended form prevented better the UV-B induced decrease in antioxidant activity of
skin tissues in these three antioxidant tests compared to those controls which do not contain active
substances (pre/post controls SP 50, SP 70). GPX level increased significantly (p < 0.05) in both pre- and
post-treatment of the compositions compared to control groups. Significant (p < 0.05) increases were
also detected after the pretreatment with compositions III, IV, VIII and IX in the level of SOD, but no
significant (p < 0.05) increase was shown in CAT levels compared to control groups. The level of MDA
(Figure 5d) in control groups and in the UVB-treated group increased after UVB exposure compared to
the untreated group. It was observed that pre-treatment and post-treatment with compositions III, IV,
and VIII, IX decreased the level of MDA, however compositions VIII, and IX, caused more reduction
in the end product of lipid peroxidation. In the pretreatment and posttreatment of these preparation
(VIII, IX) significant (p < 0.05) decreases were observed compared to control groups.
2.6. Antioxidant Activity on Guinea Pig Model
Cream formulations (III, IV, VIII, IX) containing SP 50 and SP 70 as emulsifying agents and SM
in suspended or in dissolved form with the help of TC were selected for further in vivo antioxidant
experiments according to the results of drug release studies, MTT cytotoxicity tests and in vivo TEWL
measurements. The results of antioxidant enzyme activity measurement of GPx, SOD and CAT
in epidermis of guinea pigs from different groups are summarized in Figure 6a–c. UVB exposure
induced depletion of these antioxidant enzymes in UVB treated and control groups compared to
untreated groups.
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Figure 5. Effects of pre- and post-treatment with compositions III, IV, VIII, and IX on different 
antioxidant enzyme activities in HaCaT cell line receiving acute UVB irradiation. GPX (a); SOD (b); 
CAT (c) and MDA (d) activities are expressed as % of untreated keratinocytes. Control compositions 
without SM were: pre/post controls SP 50, SP 70. Data are expressed as mean ± S.D. n = 10. In the case 
of GPX, SOD, CAT, MDA evaluations Repeated-Measures ANOVA and Pearson correlation tests 
were performed. Significant differences were marked with * and + in the figures, showing the 
significance levels in the case of compositions containing SM in suspended or dissolved forms. 
Activity assays of antioxidant enzymes from tissue samples showed that GPx, SOD and CAT 
activity was higher in the pre-treated and post- treated groups than in the control groups. In addition, 
formulations containing TC resulted in higher antioxidant enzyme activities compared to the 
formulations where SM was suspended in the creams. Significant (p < 0.05) increase was observed 
Figure 5. Effects of pre- and post-treatment with compositions III, IV, VIII, and IX on different
antioxidant enzyme activities in HaCaT cell line receiving acute UVB irradiation. GPX (a); SOD (b);
CAT (c) and MDA (d) activities are expressed as % of untreated keratinocytes. Control compositions
without SM were: pre/post controls SP 50, SP 70. Data are expressed as mean ± S.D. n = 10. In the case
of GPX, SOD, CAT, MDA evaluations Repeated-Measures ANOVA and Pearson correlation tests were
performed. Significant differences were marked with * and + in the figures, showing the significance
levels in the case of compositions containing SM in suspended or dissolved forms.
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Activity assays of antioxidant enzymes from tissue samples showed that GPx, SOD and
CAT activity was higher in the pre-treated and post- treated groups than in the control groups.
In addition, formulations containing TC resulted in higher antioxidant enzyme activities compared to
the formulations where SM was suspended in the creams. Significant (p < 0.05) increase was observed
both in GPx and CAT activity in pre comp VIII, post comp VIII and post comp IX groups compared to
control groups. Also significant (p < 0.05) increase could be detected in GPx activity in pre comp IX
group compared to control group. Beside these results, CAT activity also showed significant (p < 0.05)
increase in post comp III group.
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Figure 6. Effects of topical formulations containing silymarin in pre- and post-treatment on different
antioxidant enzyme activities in dorsal skin tissue homogenate induced by UVB irradiation. GPX (a);
SOD (b); CAT (c) and MDA (d) activities are expressed as % of enzyme activity of untreated guinea pigs.
Bars represent means ± S.D., n = 5. In case of GPX, SOD, CAT, MDA evaluations Repeated-Measures
ANOVA and Pearson correlation tests were performed. Significant differences are marked with * and +
in the figures, showing the significance levels in the case of compositions containing SM in suspended
or dissolved forms.
The SOD levels also increased significantly (p < 0.05) in two groups (pre-comp VIII and pre-
comp IX) compared to control groups. Figure 6d shows variation in MDA concentration between
groups during our experiments. Elevations in the level of end products of lipid peroxidation in the
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UVB exposed control and UVB treated groups compared to untreated group were registered. In our
experiments SM cream formulations caused a significant reduction in MDA levels in the pre-treated
and also in the post-treated groups compared to control groups. Lower significant (p < 0.05) MDA
levels were detected in the comp VIII and composition IX groups both in pre- and post-treatment.
2.7. HO-1 Enzyme Activity
Four compositions of SM formulations (III, IV, VIII, IX) were selected for the experiments according
to the results of drug release studies, MTT cytotoxicity tests and in vivo TEWL measurements. Figure 7
shows the results of HO-1 enzyme activity in epidermis of guinea pigs in pre- and post-treatment
both before and after UVB irradiation. UV-B exposure resulted in a marked increase in HO-1 enzyme
levels in UVB treated and control groups compared to untreated group. However the enzyme levels
decreased both in pre- and posttreatment of the preparations. Significant (p < 0.05) decreases were
observed in pre-comp IV, VIII and IX and post-comp III, VIII and IX groups. Asterisks show the
significance levels compared to untreated group.
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3. iscussion
In the present study, it was observed that opical composit ons formulated with different
penetration enhancers and containing Silybum marianum suspended or dis olved in Transcutol,
inhibited cellular oxidative stress in the case of pre- and post-trea ment in the hairless skin of guinea pig
and in HaCaT cells irradiated with UVB. A and UVB irradiation to ski resulted in oxi ative stress,
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and influenced the enzymatic and non-enzymatic ROS species levels [12,18]. ROS may play important
roles in photocarcinogenesis, inflammation and immune suppression as tumor initiators, tumor
promoters and inflammatory cytokine activators [30–33]. Topical supplementation of antioxidants can
provide additional protection to neutralize these ROS species both from exogenous and endogenous
sources [34].
Topical treatment with silymarin inhibits UV-induced oxidative stress in mouse models [35].
The main antioxidant components of silymarin are silibinin, silydianin and silychristin. The drawback
of topical SM dosage formulation is the low water solubility of silymarin. The different lipophilicity
of these active substances was investigated in the preformulation stage, but it just has a minor
effect on skin permeation [21,36]. In our investigation, silymarin was dissolved in TC because TC is
able to dissolve silymarin (350.1 mg/mL) and is a very strong penetration enhancer. Subsequently,
TC may affect the skin penetration and bioavailability of SM compositions. TC is a good solubilizing
agent as well as being non-toxic and biocompatible with the skin [37]. Generally, carrier systems
can promote the penetration and absorption of APIs through different barrier systems (i.e., dermal
barrier) [38]. Nevertheless, the design of these vehicles is a crucial point in drug formulation and
medicine development [24]. To develop optimal carrier systems and promote SM penetration via
the skin different non-ionic, amphiphilic tensides were selected for our ten compositions: P60, CRC,
sucrose stearate SP 50, SP 70, and SP 750. These surfactants may play a role in the solubilisation and
may also modify the bioavailability of drugs [24]. In vitro release studies provided information
about SM dissolution from the carrier systems. Release rate differences were observed among
the formulations I–X, and compositions with sucrose esters SP 50 and SP 70 (III, IV and VIII, IX)
resulted in the highest diffused SM values. Outcomes of texture analysis studies confirmed that
these creams showed optimal consistency values [39]. Although, these surfactants resulted in
good diffusion values, determination of safety and non-toxic concentration is important for their
application [27]. Biocompatibility investigations (MTT-tests) were performed on HeLa and HaCaT
cells to verify the tolerability of cream compositions. HeLa cells represent a reliable model for
testing topical preparations [40,41] while HaCaT cells are suitable to assess skin irritancy potential
of excipients [42]. In the MTT cell viability test, sucrose-esters SP 50 and SP 70 proved to be more
tolerable than Polysorbates and Cremophors in compositions. Compositions III, IV, and VIII, IX
containing these tensides (SP 50 and 70) did not reduce HeLa and HaCaT cell viabilities under 50%.
Since in vitro cytotoxicity data alone does not necessarily predict in vivo issues [43] irritancy tests
were also performed. Results of animal skin irritancy test verified that our topical preparations
containing silymarin, different surfactants and TC were highly tolerated, but after evaluation of
the preformulation study data (in vitro dissolution study, texture analysis study, in vitro (MTT-cell
viability) tests), four compositions (III, IV, VIII and IX) were selected for further in vivo antioxidant
tests on HaCaT cells and in guinea pigs. Surfactants below or under their CMCs can raise the solubility
of poorly dissolved APIs (i.e., SM), but may also influence the dissolution and the tolerability of active
components [44]. In our study formulations containing sucrose esters SP 50 and SP 70 increased the
drug solubility and drug permeability and showed good biocompatibility results.
Topical application of silymarin causes depletion of catalase and induction of cyclooxygenase
in mouse model: application of these preparations to mouse skin prevents UV-induced oxidative
stress [8]. In the present study, it was observed that every preparation containing sucrose stearate SP
50 or SP 70 increased CAT, SOD and GPx and decreased MDA activities compared to the controls.
Post-treatment of suspended and dissolved silymarin produced the same effect as pre-treatment with
different compositions. Dissolved silymarin in TC (VIII, IX) caused a more significant increase in the
activity of ROS eliminating enzymes in the case of post-treatment. Reduction in the levels of end
products of lipid peroxidation were registered after treatment with these four compositions (III, IV,
VIII, IX). Treatment with compositions VIII and IX resulted in the greatest increase of ROS species,
however the level of GPx was the highest in the case of pre- and post-treatment. It can be explained
that penetration of dissolved SM in TC was better than with compositions III and IV containing
suspended SM. Higher solubility of SM may influence the penetration and the efficacy of topical
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formulations [45]. GPx is a non-enzymatic antioxidant and maintain pro-oxidant/anti-oxidant balance
resulting in cell and tissue stabilization [12]. Those formulations that contain sucrose esters SP 50
and SP 70 may promote all ROS species at a different rate but the promotion of non-enzymatic GPx
may be more intensive. It was assumed that our in vitro data presented tight correlation with in vivo
parameters as there were an increase in activity of CAT, SOD and GPx levels compared to the controls.
Elevations in the levels of end products of lipid peroxidation were also measured on HaCaT cells.
Svobodova et al. [8] confirmed that the flavonolignan components of silymarin suppressed oxidative
stress caused by UVA and was useful in the treatment of UVA-induced skin damage. Silymarin
showed a dose-dependent protective effect against UV-induced damage in human keratinocytes via
inhibition of NF-κB activation [46]. Higher levels of SOD and CAT were measured on HaCaT in the
case of pre- and post-treatment than in guinea pig. These enzymatic ROS level activations may be
more expressed on keratinocytes due to the different effect of surfactants. The same tendency was
observed on Caco-2 cell lines treated by blends of surfactants due to the modulation of tight junction
proteins [24]. Different correlations were estimated between in vitro cell culture experiment data and
in vivo animal experiment [43].
Marked decrease in the ROS species may refer UVA and UVB-induced oxidative stress. However,
the work of Katiyar et al. [18] showed that topical application of SM inhibits UVB-induced
inflammatory responses and photocarcinogenesis in mice as well. Nevertheless, high increase of
HO-1 enzyme levels also represents stress against different environmental factors (i.e., UVB-induced
photodamage, and cellular stressors [35,47]. Many mechanisms and factors of antioxidant and
antiphotodamage activities of SM were widely studied [7]. However, there is no work which evaluates
the effect of topical formulation of SM on the modification of HO-1 enzyme activity. Both UVA and
UVB irradiation can lead to high levels of HO-1 expression of cells and are involved in an adaptive
protective response against oxidative damage and it is considered a marker of cellular oxidative
stress [35,47]. In our study, high increases of HO-1 enzyme activities were measured after UVB
irradiation. Interestingly, topical administration of SM did not affect the HO-1 activity compared
to the untreated control. It might be supposed that the high activity of antioxidant enzymes by the
rapid elimination of free radicals may influence the activation of HO-1 enzyme systems in the skin.
SM supplemented with penetration enhancers may be a potential in topical anti-inflammatory and
antioxidant therapy to the skin based on the impact of ROS species activation and moderation of HO-1
enzyme activity. Identification and characterization of pharmacological compounds that induce HO-1
in a cell-specific and cell context-specific manner deserve further attention [48].
4. Materials and Methods
4.1. Materials
SM from Silybum marianum seeds was prepared according to Kahol et al. [49]. The SM did
not contain any solvent residue. The same bioactive flavonolignans were determined as in the
standards with the help of a HPLC-MS method [4]. P60 was obtained from Sigma-Aldrich Buchs
(St. Gallen, Switzerland). TC was a kind gift from Gattefossé (Lyon, France). Cremophor A6, A25 was
obtained from BASF (Ludwigshafen, Germany). Sucrose esters (SP 50, SP 70, PS 750) were kind gifts
from Sisterna (Roosendaalc, The Netherlands). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT), Dulbecco’s Modified Eagle’s Medium (DMEM), Hank’s Balanced Salt Solution
(HBSS), phosphate buffered saline (PBS), Trypsin-EDTA, Heat-inactivated fetal bovine serum (FBS),
L-glutamine, non-essential amino acids solution, penicillin-streptomycin, were purchased from
Sigma-Aldrich). 96-Well cell plates, 12 well cell plates and culturing flasks were obtained from
Corning (Corning, New York, NY, USA). Cetostearyl alcohol, stearic acid, propylene glycol, IPM,
nipagin M were supplied by Hungaropharma Ltd., (Budapest, Hungary). HeLa cells (human cervical
cancer cells) were obtained from the European Collection of Cell Cultures (ECACC, Public Health
England, Salisbury, UK). HaCaT cells (human keratinocyte cells) were obtained from Cell Lines Service
(CLS, Heidelberg, Germany).
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4.2. Formulation of Topical Ointments
Different emulgents were used for the formulations: P60, CRC and sucrose esters (SP 50, SP 70
and PS 750). The oil-in water creams were produced by melting (60 ◦C) cetostearyl alcohol, stearic
acid and IPM and mixed in order to prepare the oil phase of the preparation. The aqueous phase
containing propylene-glycol, emulsifying agent, glycerol and purified water was heated up to the
same temperature (60 ◦C) and mixed with the oil phase, homogenized and cooled down to 25 ◦C.
Then, nipagin M was mixed in the preparation and finally, the active substance, SM. Final concentration
of the powder incorporated in the creams was 5% either in suspended form (compositions I–V) or in
dissolved form, previously dissolved with the help of TC (compositions VI–X) (Table 1).
4.3. Texture Analyzer Studies
The resistance of cream formulations was measured by a CT3 Texture Analyzer (Brookfield,
Middleboro, MA, USA). Compression test as normal test was performed. The following parameters
were fixed: trigger load (4 g), target (10 mm), speed (0.50 mm/s). A TA5 Cylinder type probe (12.7 mm
diameter, and 35 mm length) was used during the test. All measurements were done in quintuplicate.
4.4. In Vitro Release Studies
Membrane diffusion and permeability studies were performed with a vertical Franz-diffusion cell
system (Hanson Microette TM Topical and Transdermal Diffusion Cell System) [50]. Samples (0.3 g)
were placed as donor phase on cellulose-acetate membrane (pore size 0.45 µm). Pre-treatment of the
membrane by soaking in IPM was performed. Effective diffusion surface area was 1.767 cm2. 30% (v/v)
alcohol was used as an acceptor phase in order to enhance the solubility of silymarin. Rotation of the
magnetic stirrer was set to 450 rpm. The receptor medium was thermostated at 32 ± 0.5 ◦C throughout
the experiment to imitate the temperature of physiological skin on the membrane in the Franz cell.
Experiments were performed for 6 h. Samples of 0.8 mL were taken from the acceptor phase and
replaced with fresh receiving medium [51]. Quantitative measurement of silymarin was carried out
with an UV-spectrophotometer (Shimadzu, Tokyo, Japan) at a wavelength of λ = 287 nm. Calibration
curve was determined before the spectroscopic measurements of silymarin. Linear connection was
found between the concentration of silymarin and the measured absorbance. All experiments were
performed in quintuplicates.
4.5. Cell Cultures
HeLa [52] and also HaCat cell line was used in our experiments. HeLa cell is an immortalized
cell line, derived from cervical cancer cells. HeLa cells were grown in plastic cell culture flasks in
Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich Buchs), supplemented with 3.7 g/L NaHCO3,
10% (v/v) heat-inactivated fetal bovine serum (FBS), 1% (v/v) non-essential amino acids solution,
1% (v/v) L-glutamine, 100 IU/mL penicillin, and 100 IU/mL streptomycin at 37 ◦C in an atmosphere
of 5% CO2.
The immortalized human keratinocyte line HaCaT [53] has close similarity in functional
competence to normal keratinocytes. This cell line has been used in many studies as a paradigm for
epidermal cells and therefore we selected HaCaT as the other cell model. HaCaT kertinocytes were
grown in DMEM supplement with FBS (7%, v/v), streptomycin (100 U/mL), penicillin (0.1 mg/mL)
and glutamine (4 mmol/L) in a humidified atmosphere with CO2 (5%; v/v) at 37 ◦C. Culture medium
was changed twice a week for both cell types.
Cells were subcultured following trypsinization. Cells were seeded at a density of 1 × 105 cells/cm2
and grown near to confluence for experiments. The cells were routinely maintained by regular
passaging. For cytotoxic and antioxidant experiments, cells were used between passage numbers
20 and 40.
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4.6. MTT-Assay
The cytotoxic effects of compositions I–X was evaluated by a colorimetric cytotoxicity method
i.e., the MTT test [54] HaCaT keratinocytes and HeLa cell lines were used for evaluation of the in vitro
cytotoxic effects. The test was performed as follows: HaCaT and HeLa cells were seeded on flat bottom
96-well tissue culture plates at a density of 103 cells/well and allowed to grow in a CO2 incubator at
37 ◦C for 2–3 days. For these studies, the culture medium was removed, test solutions were added,
and the cells were incubated for a further 30 min. After removing the samples, the cells were washed
twice with 1 mL PBS, and another 3-h-incubation in a medium containing MTT at the concentration
of 0.5 mg/mL followed. The dark blue formazan crystals were dissolved in acidic isopropanol
(isopropanol:1.0 N hydrochloric acid = 25:1). Absorbance was measured at 570 nm against a 690 nm
reference with a FLUOstar OPTIMA Microplate Reader (BMG LABTECH, Offenburg, Germany). Cell
viability was expressed as the percentage of the untreated control [55]. Each experiment was repeated
five times with five wells for each concentration.
4.7. In Vivo Skin Irritation Test
Before in vivo antioxidant tests, formulations III, IV, VIII, IX were tested for skin irritation.
TEWL values were measured before and after 24 h application of the selected formulations to
the dorsal skin of guinea-pigs. Cream (0.1 g) was spread uniformly over a sheet of non-woven
polyethylene cloth (2 cm × 2 cm), which was then applied to the back area of a guinea-pig. Before the
experiment the dorsal skin of animals were shaved properly. The polyethylene cloth was fixed with
Tegaderm® 3M adhesive dressing (3Med Kft, Budakeszi, Hungary), and Fixomull® stretch adhesive
tape (MEDIGOR Bt., Veszprém, Hungary). After 24 h, the cloth was removed, and the treated skin area
was cleaned with a cotton wool swab. After withdrawal of the vehicle for 30 min, TEWL of the applied
skin was measured with Tewameter® (TM300, Courage & Khazaka, Köln, Germany). The temperature
and relative humidity in the laboratory were kept at 26 ◦C and 55%, respectively. The number of
samples for each experiment was five (n = 5).
4.8. UV-B Irradiation on HaCaT Cells, Pre-Treatment and Post-Treatment with Suspended and Dissolved
Silymarin in TC
Antioxidant activity of compositions I–X was determined on HaCaT cells before and after
UV-B exposure. The cells were seeded on flat bottom 12-well tissue culture plates at a density of
1 × 105 cells/well and allowed to grow in a CO2 incubator at 37 ◦C for 2–3 days. In the pre-treatment
group, culture medium was removed, test solutions i.e., SM in PBS and SM dissolved previously in
TC, then diluted with PBS (SM + TC) were added, and the cells were incubated for further 20 min.
After UV-B irradiation of 10 min. test solutions were removed, cells were washed with PBS and
incubated for 24 h. In the post-treatment group, cells were first irradiated for 10 min, then treated with
test solutions (SM and SM + TC) for 20 min. washed with PBS and incubated for 24 h. The following
parameters were used for monitoring the antioxidant capacity of different compositions on UVB
treated keratinocytes: SOD, CAT, GPx and malondialdehyde (MDA) activities. All experiments were
performed in quintuplicate.
4.9. Experimental Animals
Male Hartley guinea-pigs weighing 250–350 g were used for evaluation of dermal antioxidant
effects. The animals were fed regular rodent chow ad libitum with free access of water. The guinea-pigs
were allowed 1 week to acclimatize before the experiments and were kept at 25 ± 2 ◦C, with a relative
humidity of 55% ± 5% and a 12 h light-dark cycle. All animals included in the present study were
handled and received humane care in compliance with the National Society for Medical Research
and Guide for the Care and Use of Laboratory Animals prepared by the National Institutes of Health
(No. 10/2014/DEMÁB, extended until 2019).
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4.10. UV-B Irradiation, Pre-Treatment and Post-Treatment with Silymarin Cream Formulations, in Vivo
Pre-treatment and post-treatment with SM in different compositions of creams III, IV, VIII, IX
were tested for antioxidant capacity before and after UV-B radiation. Animals were exposed to
UV-B irradiation (acute exposure, one irradiation of 350 µW) from a distance of 20 cm. At the
beginning of the experiment dorsal skin of guinea-pigs was shaved and covered with aluminum foil
into which ten rectangular slots (0.8 cm × 1.3 cm) had been cut, next 0.1 g cream was applied to
the skin under each slot [56]. For the antioxidant studies animals were divided into two groups of
10 animals each. Guinea-pigs in group I were pre-treated topically with the cream formulations and
the vehicles (pre control SP 50 and pre control SP 70) for 20 min., then the animals were placed under
the UV-B apparatus and the uncovered skin was irradiated for 10 min. Creams were washed 24 h
after irradiation and skin samples were collected. In the II group, animals were first irradiated for
10 min., then post-treated topically with the cream formulations or vehicles (post control SP 50 and
post control SP 70) and after 24 h creams were washed and skin samples were collected. At the end
of experiment, animals were deep anesthetized with ketamine/xylazine (30–44 mg/kg, 1–5 mg/kg)
and the tissue samples were dissected. Samples were perfused and rinsed with a PBS (phosphate
buffered saline pH 7.4) solution to remove any red blood cells and clots. Skin samples were frozen
with liquid nitrogen and kept at −80 ◦C until further processing. Tissues samples (0.8 cm × 1.3 cm)
were cut from all the animals, immediately after the experiments, divided into four equal pieces for
the determination of tissue SOD, CAT, GPx and MDA activities.
4.11. Antioxidant Activity
4.11.1. Superoxide Dismutase Activity
Tissues were homogenized (Homogeniser, ×520, Ingenieurbüro CAT, M-Zipperer GmbH,
Ballrechten-Dottingen, Germany) in 20 mM HEPES buffer (1 mM EGTA, 210 mM mannitol, and 70 mM
sucrose/g tissue), pH 7.2. Then homogenate was centrifuged at 1500× g for 5 min at 4 ◦C, and the
supernatant assayed for SOD activity using the Cayman assay kit (Cayman Chemical, Ann Arbor, MI,
USA; www.caymanchem.com/pdfs/706002.pdf).
Cells (1 × 106) were collected using a rubber policeman, centrifuged at 1000× g for 10 min at
4 ◦C. Cell pellet was homogenized in cold 20 mM HEPES buffer (1 mM EGTA, 210 mM mannitol,
and 70 mM sucrose/g tissue), pH 7.2 centrifuged at 10,000× g for 15 min at 4 ◦C, and the supernatant
assayed for SOD activity using the Cayman assay kit.
4.11.2. Catalase Activity
Tissue samples were homogenized (Homogeniser, ×520) in cold buffer (50 mM potassium
phosphate, pH 7.0, containing 1 mM EDTA) per gram tissue, centrifuged at 10,000× g for 15 min at
4 ◦C, and the supernatant assayed for CAT activity using the Cayman assay kit.
Cells (1 × 106) were collected using a rubber policeman, centrifuged at 1000× g for 10 min at 4 ◦C.
Cell pellet was homogenized on ice in 2 mL cold potassium phosphate buffer, pH 7.0, containing 1 mM
EDTA per gram tissue, centrifuged at 10,000× g for 15 min at 4 ◦C, and the supernatant assayed for
CAT activity using the Cayman assay kit.
4.11.3. Glutathione Peroxidase Activity
Tissue samples were homogenized (Homogeniser, ×520) in 10 mL cold buffer containing 50 mM
Tris-HCL, pH 7.5, 5 mM EDTA and 1mM dithiothreitol, per gram tissue. The homogenate was then
centrifuged at 10,000× g for 15 min at 4 ◦C. The supernatant was assayed for GPx activity using the
Cayman assay kit.
Cells (1 × 106) were collected using a rubber policeman, centrifuged at 1000× g for 10 min at
4 ◦C. Cell pellet was homogenized in cold buffer containing 50 mM Tris-HCL, pH 7.5, 5 mM EDTA
and 1 mM dithiothreitol. The homogenate was then centrifuged at 10,000× g for 15 min at 4 ◦C.
The supernatant was assayed for GPx activity using the Cayman assay kit.
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4.11.4. Lipid Peroxidation (MDA) Test
Tissue samples (10 mg) and cells (1 × 106) were homogenized on ice in 300 µL of the MDA Lysis
Buffer containing 3 µL of BHT (100×) centrifuged at 13,000× g for 10 min to remove insoluble material.
The supernatant was assayed for Lipid Peroxidation (MDA) assay kit (Sigma-Aldrich, St. Louis, MO,
USA). Lipid peroxidation was determined by the reaction of MDA with thiobarbituric acid (TBA) to
form a colorimetric (532 nm) product, proportional to the MDA present. All antioxidant tests were
performed in quintuplicate.
4.12. Measurement of HO-1 Enzyme Activity
Activity of heme oxygenase-1 enzyme in guinea pig skin tissue was measured. Tissue samples were
homogenised in 200 mM phosphate buffer. pH 7.4. The supernatant was collected by centrifugation of
the homogenate for 30 min at 20.000× g at 4 ◦C. Assessment of heme oxygenase activity was measured
on each sample of supernatant according to protocol used by Tenhunen et al. [57]. Briefly, enzyme
activity was performed with a computer-based spectrophotometric analysis of heme formation to
bilirubin. HO-1 enzymatic assay used a reaction mixture containing, aliquot of the supernatant, plus
glucose-6-phosphate 2 mM, glucose-6-phosphate dehydrogenase 0.14 U/mL, heme 15 µM, NADPH
105 µM, rat liver cytosol as a source of recombinant biliverdin reductase 120 µg/mL, MgCl2 2 mM
and KH2PO4 100 mM. The reaction was made up to a final volume (2 mL) for each sample and
was incubated at 37 ◦C for 1h in the dark. The reaction was arrested by placing the samples on ice.
Chloroform was added to terminate the reaction and bilirubin was extracted following centrifugation,
and measured by spectrophotometric method, reading the difference in absorbance between 460 and
530 nm. The HO-1 activities were expressed in nmol of bilirubin formed per 1 milligram of protein
per hour [57].
4.13. Statistical Analysis
Data were analyzed using SigmaStat (version 3.1; SPSS, Chicago, IL, USA) and presented
as means ± S.D. Comparison of the groups in texture analyzer studies, in vitro release studies,
MTT cell viability assays., in case of SOD, CAT, MDA, GPx and HO-1 enzyme activity evaluations
Repeated-Measures ANOVA and Pearson correlation tests were performed. Significant differences
were indicated in the figures with asterisks and/or crosses. Differences were regarded as significant,
with p < 0.05. All experiments were carried out in quintuplicate and repeated at least five times (n = 5).
5. Conclusions
In our present study, silymarin topical formulations containing different surfactants and
penetration enhancers with high bioavailability were designed. These preparations showed higher
antioxidant activity against UVB-induced oxidative stress in guinea pig and HaCaT cells as pre-
and post-treatment compared to controls. Topical application of SM can influence sufficiently the
level of HO-1 enzyme which is a factor of cellular stress. The efficacy of our cream formulations is
based on the impact of ROS species activation and moderation of HO-1 enzyme activity. It can be
concluded that silymarin cream may be effective natural topical formulation to prevent and treat the
skin against UVB-irradiation
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